Therapeutic Monoclonal Antibodies and Antibody Products, Their Optimization and Drug Design in Cancers / / Edited by Veysel Kayser.
The book broadly deals with therapeutic monoclonal antibodies (mAbs) and various relevant topics, including different antibody formats such as Antibody-Drug Conjugates (ADC), bispecifics, nanoparticle-based mAbs and HER2+ cancers, immune checkpoint inhibitors and other closely related topics. Each p...
Saved in:
| TeilnehmendeR: | |
|---|---|
| Place / Publishing House: | Basel : : MDPI - Multidisciplinary Digital Publishing Institute,, 2022. ©2022 |
| Year of Publication: | 2022 |
| Language: | English |
| Physical Description: | 1 online resource (298 pages) |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| LEADER | 01740nam a2200325 i 4500 | ||
|---|---|---|---|
| 001 | 993603384804498 | ||
| 005 | 20230625200151.0 | ||
| 006 | m o d | ||
| 007 | cr ||||||||||| | ||
| 008 | 230625s2022 sz ob 001 0 eng d | ||
| 035 | |a (CKB)5400000000045940 | ||
| 035 | |a (NjHacI)995400000000045940 | ||
| 035 | |a (EXLCZ)995400000000045940 | ||
| 040 | |a NjHacI |b eng |e rda |c NjHacl | ||
| 050 | 4 | |a HD9665.5 |b .T447 2022 | |
| 082 | 0 | 4 | |a 338.476151 |2 23 |
| 245 | 0 | 0 | |a Therapeutic Monoclonal Antibodies and Antibody Products, Their Optimization and Drug Design in Cancers / |c Edited by Veysel Kayser. |
| 264 | 1 | |a Basel : |b MDPI - Multidisciplinary Digital Publishing Institute, |c 2022. | |
| 264 | 4 | |c ©2022 | |
| 300 | |a 1 online resource (298 pages) | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 588 | |a Description based on: online resource; title from PDF information screen (directory.doabooks.org, viewed June 25, 2023). | ||
| 520 | |a The book broadly deals with therapeutic monoclonal antibodies (mAbs) and various relevant topics, including different antibody formats such as Antibody-Drug Conjugates (ADC), bispecifics, nanoparticle-based mAbs and HER2+ cancers, immune checkpoint inhibitors and other closely related topics. Each paper was written by leading active research groups in their fields both from academia and industry. The book should be of interest to those scientists and researchers who develop or use biologics, biotherapeutics, biosimilars and biobetters in cancer treatment. | ||
| 504 | |a Includes bibliographical references and index. | ||
| 650 | 0 | |a Pharmaceutical industry. | |
| 776 | |z 3-0365-2687-0 | ||
| 700 | 1 | |a Kayser, Veysel, |e editor. | |
| 906 | |a BOOK | ||
| ADM | |b 2023-07-06 03:29:59 Europe/Vienna |f system |c marc21 |a 2022-04-04 09:22:53 Europe/Vienna |g false | ||
| AVE | |i DOAB Directory of Open Access Books |P DOAB Directory of Open Access Books |x https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5338132750004498&Force_direct=true |Z 5338132750004498 |b Available |8 5338132750004498 | ||